"It's a privilege to work with ABC2, and at the same time a tremendous challenge—to help find and foster the most exciting science and medicine, right up to the edge of what is possible or even conceivable. The goal is to develop new treatments for brain cancers right now. We work intimately with academic scientists, biopharmaceutical companies, as well as the patient community, and strive to capture that same spirit of innovation and risk-taking that drives continuing revolutions in the information sector. For a lab scientist like me, there is no greater pleasure and no greater sense of contribution."
Don is the Director of the Center for Drug Discovery and Associate Professor of Neurobiology at Duke University Medical Center. Don has been engaged in basic science and drug discovery research for neurological diseases for over 25 years. He received his B.S. degree from CalTech and his Ph.D. from Yale University, after which he conducted postdoctoral research at the Ludwig Institute for Cancer Research at University College London before joining the Duke faculty in 1992. In 1998, Don co-founded Cogent Neuroscience, Inc., a drug discovery company focused on developing novel approaches for the discovery and development of drugs for Huntington's disease, Alzheimer's disease, and stroke. Don served as Cogent's Chief Scientific Officer until 2002 when he returned to Duke to establish Duke's Center for Drug Discovery.